<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40350571</PMID><DateRevised><Year>2025</Year><Month>05</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2055-5822</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>May</Month><Day>11</Day></PubDate></JournalIssue><Title>ESC heart failure</Title><ISOAbbreviation>ESC Heart Fail</ISOAbbreviation></Journal><ArticleTitle>Real-world use of guideline-directed therapy for heart failure: Insights from the Danish Heart Failure Registry.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/ehf2.15320</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">We aimed to assess real-world implementation of guideline-directed medical therapy (GDMT) for heart failure (HF) with reduced ejection fraction (HFrEF) and its association with mortality and hospitalization.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We analysed 46&#xa0;816 incident HFrEF patients from the Danish Heart Failure Registry (2008-2022). We examined the utilization of GDMT-renin-angiotensin system inhibitors (RASi), beta-blockers, mineralocorticoid receptor antagonists (MRAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2i)-at 4, 8 and 12&#xa0;weeks of follow-up according to the European Society of Cardiology guidelines within the intervals 2008-2011, 2012-2015, 2016-2020 and 2021-2022. Using Cox regression, we assessed the associations between GDMTs [none (reference), 1-2 GDMTs, and 3-4 GDMTs] initiated at 4, 8 and 12&#xa0;weeks and 1 and 3&#xa0;year mortality (all-cause and cardiovascular) and hospitalization (all-cause and HF).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Between 2008-2011 and 2021-2022, RASi utilization at 4&#xa0;weeks of follow-up was 93.2% and 93.7%, respectively, and at 12&#xa0;weeks of follow-up, 97.2% and 97.8%, respectively. Beta-blocker use was 81.1% and 78.2% at 4&#xa0;weeks and 89.6% and 90.4% at 12&#xa0;weeks of follow-up while MRA utilization was 27.2% and 34.6% at 4&#xa0;weeks and 32.6% and 52.2% at 12&#xa0;weeks of follow-up. The SGLT2i use at 4&#xa0;weeks increased from 0.0% to 21.3%, and at 12&#xa0;weeks of follow-up from 3.2% to 35.8% between 2016-2020 and 2021-2022. The initiation of GDMTs at 4&#xa0;weeks of follow-up was associated with lower adjusted hazard ratios (HRs) [95% confidence intervals (CI)] for 1&#xa0;year all-cause mortality [1-2 GDMTs: 0.73 (95% CI: 0.61-0.86), 3-4 GDMTs: 0.65 (95% CI: 0.55-0.78)], 3&#xa0;year all-cause mortality [1-2 GDMTs: 0.75 (95% CI: 0.66-0.86); 3-4 GDMTs: 0.67 (95% CI: 0.59-0.76)] and 3&#xa0;year cardiovascular mortality [1-2 GDMTs: 0.74 (95% CI: 0.62-0.89); 3-4 GDMTs: 0.72 (95% CI: 0.59-0.87)]. Lower adjusted HRs were also observed for 1&#xa0;year all-cause hospitalization [1-2 GDMTs: 0.80 (95% CI: 0.75-0.86); 3-4 GDMTs: 0.78 (95% CI: 0.73-0.84)] and 3&#xa0;year all-cause hospitalization [1-2 GDMTs: 0.77 (95% CI: 0.72-0.83); 3-4 GDMTs: 0.77 (95% CI: 0.71-0.82)].</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We demonstrated high use of RASi and beta-blockers and rising use of MRA and SGLT2i, reflecting rapid adaption to guidelines changes in incident HFrEF patients. Early GDMT initiation was associated with lower 1 and 3&#xa0;year mortality and all-cause hospitalization. Upfront treatment with GDMT, according to the latest guidelines, is crucial.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). ESC Heart Failure published by John Wiley &amp; Sons Ltd on behalf of European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schj&#xf8;dt</LastName><ForeName>Inge</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-4086-2281</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valentin</LastName><ForeName>Jan B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnsen</LastName><ForeName>S&#xf8;ren P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mols</LastName><ForeName>Rikke E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Egstrup</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Unit, Odense University Hospital, Svendborg, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Center of Excellence, Odense University Hospital, Odense, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf8;gstrup</LastName><ForeName>Brian B</ForeName><Initials>BB</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Novartis Healthcare A/S, Denmark</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>ESC Heart Fail</MedlineTA><NlmUniqueID>101669191</NlmUniqueID><ISSNLinking>2055-5822</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">guidelines</Keyword><Keyword MajorTopicYN="N">guideline&#x2010;directed medical therapy</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">implementation</Keyword><Keyword MajorTopicYN="N">outcomes</Keyword><Keyword MajorTopicYN="N">utilization</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>12</Day><Hour>0</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40350571</ArticleId><ArticleId IdType="doi">10.1002/ehf2.15320</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599&#x2010;3726. doi:10.1093/eurheartj/ehab368</Citation></Reference><Reference><Citation>Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 2023;118:3272&#x2010;3287. doi:10.1093/cvr/cvac013</Citation></Reference><Reference><Citation>Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145:e895&#x2010;e1032. doi:10.1161/CIR.0000000000001063</Citation></Reference><Reference><Citation>Kim SE, Yoo BS. Treatment strategies of improving quality of care in patients with heart failure. Korean Circ J 2023;53:294&#x2010;312. doi:10.4070/kcj.2023.0024</Citation></Reference><Reference><Citation>Savarese G, Kishi T, Vardeny O, Adamsson Eryd S, Bodeg&#xe5;rd J, Lund LH, et al. Heart failure drug treatment&#x2010;inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF). JACC Heart Fail 2023;11:1&#x2010;14. doi:10.1016/j.jchf.2022.08.009</Citation></Reference><Reference><Citation>Stolfo D, Lund LH, Becher PM, Orsini N, Thorvaldsen T, Benson L, et al. Use of evidence&#x2010;based therapy in heart failure with reduced ejection fraction across age strata. Eur J Heart Fail 2022;24:1047&#x2010;1062. doi:10.1002/ejhf.2483</Citation></Reference><Reference><Citation>Dickstein K, Cohen&#x2010;Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole&#x2010;Wilson PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933&#x2010;989. doi:10.1016/j.ejheart.2008.08.005</Citation></Reference><Reference><Citation>McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, B&#xf6;hm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803&#x2010;869. doi:10.1093/eurjhf/hfs105</Citation></Reference><Reference><Citation>Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891&#x2010;975. doi:10.1002/ejhf.592</Citation></Reference><Reference><Citation>McMurray JJV, Packer M. How should we sequence the treatments for heart failure and a reduced ejection fraction? Circulation 2021;143:875&#x2010;877. doi:10.1161/CIRCULATIONAHA.120.052926</Citation></Reference><Reference><Citation>Schmidt M, Schmidt SAJ, Adelborg K, Sundboll J, Laugesen K, Ehrenstein V, et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol 2019;11:563&#x2010;591. doi:10.2147/CLEP.S179083</Citation></Reference><Reference><Citation>Schj&#xf8;dt I, Nakano A, Egstrup K, Cerqueira C. The Danish Heart Failure Registry. Clin Epidemiol 2016;8:497&#x2010;502. doi:10.2147/CLEP.S99504</Citation></Reference><Reference><Citation>Pedersen CB. The Danish Civil Registration System. Scand J Public Health 2011;39:22&#x2010;25. doi:10.1177/1403494810387965</Citation></Reference><Reference><Citation>Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 2015;7:449&#x2010;490. doi:10.2147/CLEP.S91125</Citation></Reference><Reference><Citation>Pottegard A, Schmidt SAJ, Wallach&#x2010;Kildemoes H, Sorensen HT, Hallas J, Schmidt M. Data resource profile: the Danish National Prescription Registry. Int J Epidemiol 2017;46:798&#x2010;798f. doi:10.1093/ije/dyw213</Citation></Reference><Reference><Citation>Helweg&#x2010;Larsen K. The Danish Register of Causes of Death. Scand J Public Health 2011;39:26&#x2010;29. doi:10.1177/1403494811399958</Citation></Reference><Reference><Citation>Jensen VM, Rasmussen AW. Danish education registers. Scand J Public Health 2011;39:91&#x2010;94. doi:10.1177/1403494810394715</Citation></Reference><Reference><Citation>Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments. Scand J Public Health 2011;39:103&#x2010;105. doi:10.1177/1403494811405098</Citation></Reference><Reference><Citation>Andersen C, Schj&#xf8;dt I, Nakano A, Johnsen SP, Egstrup K, L&#xf8;gstrup BB. The Danish Heart Failure Registry: a validation study of content. Clin Epidemiol 2022;14:1585&#x2010;1594. doi:10.2147/CLEP.S390898</Citation></Reference><Reference><Citation>Sharma A, Verma S, Bhatt DL, Connelly KA, Swiggum E, Vaduganathan M, et al. Optimizing foundational therapies in patients with HFrEF. How do we translate these findings into clinical care? Translation of the document prepared by the Czech Society of Cardiology. Cor Vasa 2022;64:441&#x2010;454. doi:10.33678/cor.2022.079</Citation></Reference><Reference><Citation>von Scheidt W, Zugck C, Pauschinger M, Hambrecht R, Bruder O, Hartmann A, et al. Characteristics, management modalities and outcome in chronic systolic heart failure patients treated in tertiary care centers: results from the EVIdence based TreAtment in Heart Failure (EVITA&#x2010;HF) registry. Clin Res Cardiol 2014;103:1006&#x2010;1014. doi:10.1007/s00392&#x2010;014&#x2010;0743&#x2010;x</Citation></Reference><Reference><Citation>Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP&#x2010;HF Registry. J Am Coll Cardiol 2018;72:351&#x2010;366. doi:10.1016/j.jacc.2018.04.070</Citation></Reference><Reference><Citation>Maddox TM, Song Y, Allen J, Chan PS, Khan A, Lee JJ, et al. Trends in U.S. ambulatory cardiovascular care 2013 to 2017. J Am Coll Cardiol 2020:93&#x2010;112. doi:10.1016/j.jacc.2019.11.011</Citation></Reference><Reference><Citation>Kap&#x142;on&#x2010;Cie&#x15b;licka A, Benson L, Chioncel O, Crespo&#x2010;Leiro MG, Coats AJS, Anker SD, et al. A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction &#x2010; insights from the ESC&#x2010;HFA EORP Heart Failure Long&#x2010;Term Registry. Eur J Heart Fail 2022;24:335&#x2010;350. doi:10.1002/ejhf.2408</Citation></Reference><Reference><Citation>D'Amario D, Rodolico D, Rosano GMC, Dahlstr&#xf6;m U, Crea F, Lund LH, et al. Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry. Eur J Heart Fail 2022;24:871&#x2010;884. doi:10.1002/ejhf.2477</Citation></Reference><Reference><Citation>Greene SJ, Ayodele I, Pierce JB, Khan MS, Lewsey SC, Yancy CW, et al. Eligibility and projected benefits of rapid initiation of quadruple medical therapy for newly diagnosed heart failure. JACC Heart Fail 2024;12:1365&#x2010;1377. doi:10.1016/j.jchf.2024.03.001</Citation></Reference><Reference><Citation>Thorvaldsen T, Benson L, Dahlstr&#xf6;m U, Edner M, Lund LH. Use of evidence&#x2010;based therapy and survival in heart failure in Sweden 2003&#x2013;2012. Eur J Heart Fail 2016;18:503&#x2010;511. doi:10.1002/ejhf.496</Citation></Reference><Reference><Citation>McMurray JJV, Solomon SD, Inzucchi SE, K&#xf8;ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995&#x2010;2008. doi:10.1056/NEJMoa1911303</Citation></Reference><Reference><Citation>Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:1413&#x2010;1424. doi:10.1056/NEJMoa2022190</Citation></Reference><Reference><Citation>Stolfo D, Lund LH, Benson L, Lindberg F, Ferrannini G, Dahlstr&#xf6;m U, et al. Real&#x2010;world use of sodium&#x2010;glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: data from the Swedish Heart Failure Registry. Eur J Heart Fail 2023;25:1648&#x2010;1658. doi:10.1002/ejhf.2971</Citation></Reference><Reference><Citation>Pierce JB, Vaduganathan M, Fonarow GC, Ikeaba U, Chiswell K, Butler J, et al. Contemporary use of sodium&#x2010;glucose cotransporter&#x2010;2 inhibitor therapy among patients hospitalized for heart failure with reduced ejection fraction in the US: the Get With The Guidelines&#x2013;Heart Failure Registry. JAMA Cardiol 2023;8:652&#x2010;661. doi:10.1001/jamacardio.2023.1266</Citation></Reference><Reference><Citation>Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR). Eur Heart J 2016;37:2315&#x2010;2381. doi:10.1093/eurheartj/ehw106</Citation></Reference><Reference><Citation>Savarese G, Dahlstrom U, Vasko P, Pitt B, Lund LH. Association between renin&#x2013;angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score&#x2010;matched cohort study. Eur Heart J 2018;39:4257&#x2010;4265. doi:10.1093/eurheartj/ehy621</Citation></Reference><Reference><Citation>Hamada T, Kubo T, Kawai K, Nakaoka Y, Yabe T, Furuno T, et al. Frailty interferes with the guideline&#x2010;directed medical therapy in heart failure patients with reduced ejection fraction. ESC Heart Fail 2023;10:223&#x2010;233. doi:10.1002/ehf2.14163</Citation></Reference><Reference><Citation>Schj&#xf8;dt I, Kn&#xf8;fler I, Gislason G, Dridi NP, Villumsen P, Christensen PM, et al. The Danish Heart Failure Registry: high degree of compliance in medical treatment [Dansk Hjertesvigtdatabase: H&#xf8;j grad af compliance i den medicinske behandling] Dan Med J 2024. https://ugeskriftet.dk/videnskab/dansk&#x2010;hjertesvigtdatabase&#x2010;hoj&#x2010;grad&#x2010;af&#x2010;compliance&#x2010;i&#x2010;den&#x2010;medicinske&#x2010;behandling. Accessed 6 June 2024</Citation></Reference><Reference><Citation>Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, et al. Improving evidence&#x2010;based care for heart failure in outpatient cardiology practices: primary results of the registry to improve the use of evidence&#x2010;based heart failure therapies in the outpatient setting (IMPROVE HF). Circulation 2010;122:585&#x2010;596. doi:10.1161/circulationaha.109.934471</Citation></Reference><Reference><Citation>Savarese G, Lund LH, Dahlstr&#xf6;m U, Str&#xf6;mberg A. Nurse&#x2010;led heart failure clinics are associated with reduced mortality but not heart failure hospitalization. J Am Heart Assoc 2019;8:e011737. doi:10.1161/jaha.118.011737</Citation></Reference><Reference><Citation>Greene SJ, Butler J, Fonarow GC. Simultaneous or rapid sequence initiation of quadruple medical therapy for heart failure&#x2014;optimizing therapy with the need for speed. JAMA Cardiol 2021;6:743&#x2010;744. doi:10.1001/jamacardio.2021.0496</Citation></Reference><Reference><Citation>Schj&#xf8;dt I, Johnsen SP, Str&#xf6;mberg A, DeVore AD, Valentin JB, L&#xf8;gstrup BB. Evidence&#x2010;based process performance measures and clinical outcomes in patients with incident heart failure with reduced ejection fraction: a Danish nationwide cohort study. Circ Cardiovasc Qual Outcomes 2022;15:e007973. doi:10.1161/circoutcomes.121.007973</Citation></Reference><Reference><Citation>Schrage B, Lund LH, Benson L, Dahlstr&#xf6;m U, Shadman R, Linde C, et al. Predictors of primary prevention implantable cardioverter&#x2010;defibrillator use in heart failure with reduced ejection fraction: impact of the predicted risk of sudden cardiac death and all&#x2010;cause mortality. Eur J Heart Fail 2022;24:1212&#x2010;1222. doi:10.1002/ejhf.2530</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>